Tuesday, 9 February 201608:00 | Registration | |
Session Chair: Mark Cragg, University of Southampton |
| | 09:00 | | 09:45 | Protein Knockout Mice: A Novel in vivo Validation Approach for Membrane Targets
Stefan Dubel, Full Professor and Director, Technische Universität Braunschweig, Germany
A new tool for functional target discovery and validation are protein knockdown mice. From phage display selection of human antibodies to the mouse knockdown phenotype induced by the antibody, a single cloning step is needed. | 10:15 | Full in vitro Selection of Synthetic and Humanized Single Domain Antibodies for Research and Therapeutic Applications
Franck Perez, Group Leader, Institut Curie, France
Single domain antibodies represent an attractive alternative to classical immunoglobulins to identify, label and target antigens. We created a synthetic library that can be fully screened in vitro. Selections against intracellular and cell surface antigens will be reported here. | 10:45 | Coffee & Networking in Exhibition Hall | 11:15 | Case Study: Bi-specific Redirected T-cell Immunotherapy Targeting P-cadherin Expressing Tumors
Lioudmila Tchistiakova, Senior Director, Pfizer Inc, United States of America
| 11:45 | Roche's Approach to Discover, Design, Develop and Deliver Next Generation Protein Therapeutics
Stefan Weigand, Head of Large Molecule Research, F. Hoffmann-La Roche Ltd, Germany
My presentation will start with a problem statement regarding complexity of disease, pick up on diversity generation during binder generation, selection of best format (like bi-specifics, small-large molecule combos, brain-shuttle molecules) during LO phase, and end with showcasing that complex biologics can be produced for clinic with similar efficiency as IgGs - given the right set-up. | 12:15 |  Technology Spotlight:
Screening and Characterisation of Biologics using a High Sensitivity Plate-based Laser Scanning Cytometer
Paul Wylie, Product Manager, TTP LabTech Ltd
The mirrorball fluorescence cytometer is applicable to many stages within biologics discovery from screening to binding characterisation and monitoring phenotypic responses. Streamlined no wash cell or bead-based assays provide process efficiencies over standard Flow or ELISA formats, enabling you to do more with precious samples and time.
| 12:30 | Lunch & Networking in Exhibition Hall | 13:30 | Poster Viewing Session | |
Session Chair: Franck Perez, Institut Curie | Session Sponsors |
| | 14:15 |  Technology Spotlight:
Cell-Based Bioassays And Reagents For Therapeutic Antibody Discovery And Characterisation
Craig Malcolm, Strategic Collaborations Manager, Promega UK Ltd
This technology snapshot presentation will introduce a range of technologies from Promega applicable to early stage discovery and characterisation of antibodies in addition to functional cell-based bioassays for potency and lot-release.
| 14:30 |  | Keynote Presentation Antibody Based Cancer Immunotherapy
Christian Klein, Expert Scientist/Head, Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Switzerland
The lecture will cover the development of obinutuzumab, a glycoengineered Type II CD20 antibody, novel IL2v based immunocytokines and a novel T cell bispecific antibody platform. |
| 15:15 | Coffee & Networking in Exhibition Hall | 15:45 | CANCELLED DUE TO ILL HEALTH - Targeting Cancer with BiTE® Antibody Constructs
Roman Kischel, Principal Scientist, Amgen Research, Germany
The presentation will demonstrate the structure and mode of action of BiTE® antibody constructs. Clinical and preclinical data for different BiTE® antibody constructs will be discussed. | 15:45 | A Novel Biparatopic Approach to Target Cancer Cells
John Li, Senior Scientist, MedImmune, United States of America
This talk will focus on the development of a bispecific biparatopic antibody conjugated to a cytotoxic drug to treat patients that are either refractory or ineligible for the current HER2 targeted therapies. | 16:15 | Single Domain Antibodies: From Conformational Sensors to Bispecific Antibodies for Immunotherapy
Patrick Chames, Main Scientist, INSERM, France
We are using single domain antibodies as innovative tools. Biosensors which are able to capture the conformation states of some membrane receptors such as EGFR or mGluRs, or as building blocks to create bispecific immune modulators. | 16:45 | Driving Innovation in Antibody Discovery and Development through Novel Partnership Models
Robert Williams, Chief Drug Development Scientist, Cancer Research UK, United Kingdom
This presentation will give an overview of this business framework with illustrative examples. | 17:15 | Drinks Reception |
Wednesday, 10 February 2016 |
Session Chair: Stefan Dubel, Technical University of Braunschweig |
| | 09:00 |  | Keynote Presentation Antibodies to GPCRs A New Therapeutic Approach
Paul Insel, Vice-Chair and Distinguished Professor, Pharmacology, University of California San Diego, United States of America
G-protein coupled receptors (GPCRs) are the largest class of therapeutic targets for approved drugs. Virtually all these drugs are small molecules or peptides but recent evidence suggests that antibodies to GPCRs may be a novel therapeutic approach. |
| 10:00 | Targeting ION Channels with Biologics
Tristan Vaughan, Vice President, R&D, Antibody Discovery and Protein Engineering, MedImmune Ltd, United Kingdom
Successful approaches targeting ion channels will be described and a case study presented on the discovery of ion channel modulating antibodies. | 10:45 | Coffee & Networking in Exhibition Hall | 11:15 | Advanced Targeting with Chimeric Antigen Receptors
Martin Pule, Director Chimeric Antigen Receptor (CAR) Programme. Founder & Chief Scientific Officer, UCL Autolus, United Kingdom
| 11:45 | OptiLinked FDCs: Fully Armed Antibody Fragment Drug Conjugates
Mahendra Deonarain, Chief Science & Operating Officer, Antikor Biopharma Ltd, United Kingdom
| 12:15 |  Technology Spotlight:
Advancing Antibody Discovery with True Multiplex Screening and the iQue Screener Platform
Steve Davenport, VP European Sales, Intellicyte
Multiplexed high throughput screening is becoming an integral component in the discovery of therapeutic antibodies because it increases confidence in screening hits, improves workflow and enables the identification of lead candidates with increased functionality. With the iQue Screener platform, scientists are using suspension assay formats and encoding technology to develop powerful high content screens for their antibody libraries.
| 12:30 | Lunch & Networking in Exhibition Hall | 13:30 | Poster Viewing Session | |
Session Chair: Paul Insel, UCSD |
| | 14:00 | Discovery and Manufacturing Strategies for Novel, Homogeneous ADC Molecules Using Xpress CF™ Cell-Free Expression Technology
Trevor Hallam, Chief Scientific Officer, Sutro Biopharma Inc, United States of America
| 14:30 | Sortase-mediated Antibody Conjugation (SMAC™): Generation of Homogeneous, Site-specifically Conjugated Antibody Drug Conjugates
Roger Beerli, CSO, NBE Therapeutics, Switzerland
This presentation describes a novel enzymatic conjugation platform that provides a robust and efficient means to attach toxic payloads to antibodies and yields homogenous drug products with pre-defined drug-to-antibody ratios. | 15:00 | Coffee & Networking in Exhibition Hall | 15:30 | Integration of High Throughput ‘Omic Platforms into Antibody Discovery
John Castle, Executive Director, Vaccine Research and Translational Medicine, Agenus Switzerland Inc., Switzerland
We use ‘omics technologies to identify and develop novel immune cell receptors. Our workflow harnesses cellular display, next-generation sequencing, mass-spec, bio data, biostatistics, and computational immunology from discovery to regulatory filing. | 16:00 | Close of Conference |
|
Add to Calendar ▼2016-02-09 00:00:002016-02-10 00:00:00Europe/LondonAntibodies in Drug DiscoveryAntibodies in Drug Discovery in Cambridge, UKCambridge, UKSELECTBIOenquiries@selectbiosciences.com
